Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_4
1
20%
Ph phase_1
3
60%
Ph phase_2
1
20%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (60.0%)
Phase 21 (20.0%)
Phase 41 (20.0%)

Trials by Status

unknown120%
completed240%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)

NCT06242691
completedphase_1

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

NCT03448393
terminatedphase_1

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

NCT02592707
unknownphase_2

Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)

NCT03050866
terminatedphase_4

Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery

NCT02724033

Clinical Trials (5)

Showing 5 of 5 trials
NCT06242691Phase 1

Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)

Completed
NCT03448393Phase 1

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Completed
NCT02592707Phase 1

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Terminated
NCT03050866Phase 2

Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)

Unknown
NCT02724033Phase 4

Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5